These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33177621)

  • 1. Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
    Luszczak S; Simpson BS; Stopka-Farooqui U; Sathyadevan VK; Echeverria LMC; Kumar C; Costa H; Haider A; Freeman A; Jameson C; Ratynska M; Ben-Salha I; Sridhar A; Shaw G; Kelly JD; Pye H; Gately KA; Whitaker HC; Heavey S
    Sci Rep; 2020 Nov; 10(1):19870. PubMed ID: 33177621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retraction Note: HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation.
    Sun S; Zhang Y; Zheng J; Duan B; Cui J; Chen Y; Deng W; Ye B; Liu L; Chen Y; Du J; Gu L
    Cell Death Dis; 2019 Aug; 10(9):633. PubMed ID: 31439830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Author Correction: Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib.
    Pan H; Wang Z; Jiang L; Sui X; You L; Shou J; Jing Z; Xie J; Ge W; Cai X; Huang W; Han W
    Sci Rep; 2020 Oct; 10(1):16974. PubMed ID: 33028954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    Yang X; Niu B; Wang L; Chen M; Kang X; Wang L; Ji Y; Zhong J
    Oncol Lett; 2016 Jul; 12(1):102-106. PubMed ID: 27347108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrocyclization as a Source of Desired Polypharmacology. Discovery of Triple PI3K/mTOR/PIM Inhibitors.
    Martínez-González S; Alvarez RM; Martín JI; García AB; Riesco-Fagundo C; Varela C; Rodríguez Hergueta A; González Cantalapiedra E; Albarrán MI; Gómez-Casero E; Cebriá A; Aguirre E; Ajenjo N; Cebrián D; Di Geronimo B; Cunningham D; O'Neill M; Dave HPG; Blanco-Aparicio C; Pastor J
    ACS Med Chem Lett; 2021 Nov; 12(11):1794-1801. PubMed ID: 34795869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Author Correction: Verbascoside: Identification, Quantification, and Potential Sensitization of Colorectal Cancer Cells to 5-FU by Targeting PI3K/AKT Pathway.
    Attia YM; El-Kersh DM; Wagdy HA; Elmazar MM
    Sci Rep; 2019 Dec; 9(1):18659. PubMed ID: 31796874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
    Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
    Dey N; Sun Y; Carlson JH; Wu H; Lin X; Leyland-Jones B; De P
    Am J Cancer Res; 2016; 6(4):714-46. PubMed ID: 27186427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
    Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway.
    Li A; Zhang R; Zhang Y; Liu X; Wang R; Liu J; Liu X; Xie Y; Cao W; Xu R; Ma Y; Cai W; Wu B; Cai S; Tang X
    Am J Transl Res; 2019; 11(9):5573-5585. PubMed ID: 31632530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.
    Zhu W; Fu W; Hu L
    Cancer Biother Radiopharm; 2013 Nov; 28(9):665-73. PubMed ID: 23768063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype.
    Hong SW; Shin JS; Moon JH; Kim YS; Lee J; Choi EK; Ha SH; Lee DH; Chung HN; Kim JE; Kim KP; Hong YS; Lee JL; Lee WJ; Choi EK; Lee JS; Jin DH; Kim TW
    Apoptosis; 2014 May; 19(5):895-904. PubMed ID: 24652480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.
    Potiron VA; Abderrahmani R; Giang E; Chiavassa S; Di Tomaso E; Maira SM; Paris F; Supiot S
    Radiother Oncol; 2013 Jan; 106(1):138-46. PubMed ID: 23321494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.
    Lunardi A; Ala U; Epping MT; Salmena L; Clohessy JG; Webster KA; Wang G; Mazzucchelli R; Bianconi M; Stack EC; Lis R; Patnaik A; Cantley LC; Bubley G; Cordon-Cardo C; Gerald WL; Montironi R; Signoretti S; Loda M; Nardella C; Pandolfi PP
    Nat Genet; 2020 Oct; 52(10):1132. PubMed ID: 32884149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction: SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
    Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Sun C; Han B
    Cell Death Dis; 2019 Oct; 10(11):799. PubMed ID: 31641102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Author Correction: The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.
    Wu SR; Teng CH; Tu YT; Ko CJ; Cheng TS; Lan SW; Lin HY; Lin HH; Tu HF; Hsiao PW; Huang HP; Chen CH; Lee MS
    Sci Rep; 2020 Feb; 10(1):2874. PubMed ID: 32051516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.